Clinical Trials: Setting up Your Cannabis Research Study
| | |

Clinical Trials: Setting up Your Cannabis Research Study

There is widespread demand for access to medicinal cannabis products by patients. Yet very few Australian doctors currently prescribe cannabinoid-derived medications. Will emerging clinical trial evidence reduce the reluctance of GPs to prescribe these medications? In this blog, we’ll provide a basic overview of setting up a clinical research trial for medicinal cannabis. Reading time:…

TGA GMP Manufacturing licence for Medicinal Cannabis
|

TGA GMP Manufacturing licence for Medicinal Cannabis

This blog is intended as a current guide how to set about applying for a TGA GMP Manufacturing license for Medicinal Cannabis. Process for applying for a TGA GMP Manufacturing Licence Two Manufacturing Licences may be required for the manufacture of medicinal cannabis active pharmaceutical ingredients (API), for example, if: extracting or purify the cannabis…

How to apply for a medicinal cannabis licence
|

How to apply for a medicinal cannabis licence

On October 31, the ODC released an online smart form and “flat” paper forms to apply for a cultivation, production or research medicinal cannabis licence. This online form can also be used if you seek a manufacturing licence but ONLY if you are also applying for a cultivation and/or production licence or a research licence….

TGA issues new Australian Complementary Medicine Guidelines
|

TGA issues new Australian Complementary Medicine Guidelines

Previously we wrote about the TGA planning to revise the complementary medicine guidelines. On the 13 October 2016 the Australian TGA released the sixth version of the Australian regulatory guidelines for complementary medicines ARGCM, Version 6.0, October 2016 this is is the fifth update of the Australian Complementary Medicine Guidelines since 2013. This is This short blog is to draw your attention to…

Medicinal cannabis licensing and regulations in a (large) nut shell
|

Medicinal cannabis licensing and regulations in a (large) nut shell

The recent scheduling changes to medicinal cannabis, which includes cannabidiol (abbreviated as “CBD”) and tetrahydrocannabinols (“THC”), moving it from Schedule 9 (prohibited substance) to Schedule 8 (controlled substance). This change, coupled with the rapidly evolving legislative changes around both cultivation and patient access to medicinal cannabis, have many Australian cultivator and manufacturing innovators on high…